Effects of Maplirpacept (PF-07901801), Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase 1b/2 Study of PF-07901801, A CD47 Blocking Agent, With Tafasitamab and Lenalidomide for Participants With Relapsed/Refractory Diffuse Large B Cell Lymphoma not Eligible for Stem Cell Transplantation
Category & Conditions: Cancer
Medicine: Maplirpacept
ClinicalTrials.gov Identifier (NCT): NCT05626322
Protocol ID: C4971003
Open Plain Language Summary Result:
Click here